CVX Vs XOM Stock, Which Energy Play Is Best?
Chevron (NYSE:CVX) and Exxon Mobil (NYSE:XOM) are two of the…
Sell
44
RSMDF Quote, Financials, Valuation and Earnings
Last price:
$22.00
Seasonality move
:
16.66%
Day range:
$22.00 - $22.00
52-week range:
$17.70 - $30.00
Dividend yield:
0.96%
P/E ratio:
24.69x
P/S ratio:
6.46x
P/B ratio:
5.82x
Volume:
--
Avg. volume:
71
1-year change:
24.29%
Market cap:
$32.3B
Revenue:
$4.7B
EPS (TTM):
$0.89
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, ResMed has -- downside to fair value with a price target of -- per share.
RSMDF vs. S&P 500
-
Over the past 5 trading days, ResMed has overperformed the S&P 500 by 1.23% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
ResMed does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
ResMed has grown year-over-year revenues for 16 quarters straight. In the most recent quarter ResMed reported revenues of $1.3B.
Earnings Growth
-
ResMed has grown year-over-year earnings for 5 quarters straight. In the most recent quarter ResMed reported earnings per share of $0.25.
Enterprise value:
32B
EV / Invested capital:
5.15x
Price / LTM sales:
6.46x
EV / EBIT:
20.80x
EV / Revenue:
6.37x
PEG ratio (5yr expected):
0.67x
EV / Free cash flow:
20.52x
Price / Operating cash flow:
20.80x
Enterprise value / EBITDA:
18.24x
Gross Profit (TTM):
$3B
Return On Assets:
18.44%
Net Income Margin (TTM):
26.15%
Return On Equity:
25.76%
Return On Invested Capital:
22.47%
Operating Margin:
33%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $4B | $4.6B | $5B | $1.2B | $1.3B | |
| Gross Profit | $2.3B | $2.6B | $3B | $692.8M | $766.4M | |
| Operating Income | $1.1B | $1.3B | $1.6B | $374.6M | $426.3M | |
| EBITDA | $1.3B | $1.5B | $1.8B | $429.2M | $478.2M | |
| Diluted EPS | $0.59 | $0.65 | $0.89 | $0.20 | $0.25 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.5B | $1.7B | $2.3B | $2.4B | $3.2B | |
| Total Assets | $4.6B | $4.9B | $6.7B | $6.8B | $7.6B | |
| Current Liabilities | $876.5M | $667.3M | $761.7M | $773M | $940.5M | |
| Total Liabilities | $1.9B | $1.6B | $2.8B | $2.2B | $2B | |
| Total Equity | $2.7B | $3.3B | $3.9B | $4.6B | $5.5B | |
| Total Debt | $731M | $680.7M | $1.6B | $1B | $673M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $535.3M | $1.2B | $1.7B | $402M | $578.7M | |
| Cash From Investing | -$1.2B | -$269.8M | -$112.8M | -$33.2M | -$31.8M | |
| Cash From Financing | $669M | -$914.6M | -$835.6M | -$335.9M | -$144.1M | |
| Free Cash Flow | $407.7M | $1.1B | $1.6B | $378.9M | $554.9M | |
RSMDF
Sector
Market Cap
$32.3B
$34.5M
Price % of 52-Week High
73.33%
43.57%
Dividend Yield
0.96%
0%
Shareholder Yield
1.35%
-0.79%
1-Year Price Total Return
24.29%
-42.08%
Beta (5-Year)
0.634
0.660
Dividend yield:
0.96%
Annualized payout:
$0.19
Payout ratio:
23.14%
Growth streak:
4 years
Technicals
8-day SMA
Sell
Level
$23.00
200-day SMA
Buy
Level
$21.66
Bollinger Bands (100)
Sell
Level
21.39 - 28.41
Chaikin Money Flow
Sell
Level
-806.8K
20-day SMA
Sell
Level
$27.10
Relative Strength Index (RSI14)
Sell
Level
11.79
ADX Line
Sell
Level
68.12
Williams %R
Buy
Level
-96.0384
50-day SMA
Sell
Level
$27.38
MACD (12, 26)
Sell
Level
-1.81
25-day Aroon Oscillator
Sell
Level
-48
On Balance Volume
Neutral
Level
3.1M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (10.3486)
Buy
CA Score
(Annual)
Level (1.4073)
Buy
Beneish M-Score
(Annual)
Level (-2.4845)
--
Momentum Score
Level (--)
Buy
Ohlson Score
Level (-3.4093)
Buy
Piotroski F Score
(Annual)
Level (6)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (10)
Revenue Forecast
Earnings per Share Forecast
Company Profile
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Stock Forecast FAQ
In the current month, RSMDF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The RSMDF average analyst price target in the past 3 months is --.
-
Where Will ResMed Stock Be In 1 Year?
According to analysts, the consensus estimate is that ResMed share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About ResMed?
Analysts are divided on their view about ResMed share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that ResMed is a Sell and believe this share price will rise from its current level to --.
-
What Is ResMed's Price Target?
The price target for ResMed over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is RSMDF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for ResMed is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of RSMDF?
You can purchase shares of ResMed via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase ResMed shares.
-
What Is The ResMed Share Price Today?
ResMed was last trading at $22.00 per share. This represents the most recent stock quote for ResMed. Yesterday, ResMed closed at $22.00 per share.
-
How To Buy ResMed Stock Online?
In order to purchase ResMed stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is it Safe to Invest in Google With OpenAI Threats?
For the last 20 years, Google parent company Alphabet (NASDAQ:GOOG,…
Is Broadcom Stock a Millionaire Maker?
Broadcom (Nasdaq: AVGO) stock has gone up more than 64%…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Buy
60
RGC alert for May 8
Regencell Bioscience Holdings [RGC] is up 22.52% over the past day.
Buy
52
SRPT alert for May 8
Sarepta Therapeutics [SRPT] is down 21.54% over the past day.
Buy
74
LIVN alert for May 8
LivaNova PLC [LIVN] is up 23.38% over the past day.
